First Successful Total Knee Replacement Performed in the U.S. Using Pixee Medical’s Knee+ Augmented-Reality Platform

Pixee Medical’s Knee+ AR computer-assisted orthopedic solution deployed for the first-ever use in the United States with the MicroPort Evolution® Medial-Pivot Knee system

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, today announces the successful completion of the first surgery in the U.S. utilizing Pixee Medical, an FDA-cleared augmented reality surgical application for assistance in total knee arthroplasties.

The surgery was performed by Dr. Antonia F. Chen, M.D., M.B.A., an orthopedic surgeon at Brigham and Women’s Hospital in Boston, MA, using MicroPort Orthopedics Evolution® Medial-Pivot Knee system, designed to deliver a high degree of stability and motion, leading to increased patient satisfaction and survivorship. In conjunction with Pixee’s Knee+ platform, the surgeon is able to achieve excellent precision and control, which may result in more efficiency in the operating room and a quicker return to full function for the patient.
Pixee Medical’s Knee+ is a patented platform designed to assist orthopedic surgeons to perform surgeries better and faster by providing real-time positioning of instruments, right in their field of view via smartglasses. Knee+ is intuitive and requires minimal training since it does not change the overall technique for 90 percent of surgeons who use a conventional technique but have never utilized navigation or robots.
“Our mission at MicroPort is to help the patient achieve full function, faster – and this ability to enhance precision and results during surgery will do just that,” said Benny Hagag, President of MicroPort Orthopedics. “The Pixee platform will be transformative in the continued efficiency and precision of our device systems.”
“The first use of Knee+ in Boston is an important step forward as the U.S. represents 50 percent of the worldwide market,” said Sébastien Henry, Founder and CEO of Pixee Medical. “Pixee’s platform is designed to become the cornerstone of data acquisition and exchange during surgery. We look forward to expanding the use of this technology within the US market.”
MicroPort Orthopedics offers various products and techniques to help patients receiving total hip and knee replacements achieve Full Function, Faster. For more information on MicroPort Orthopedics, visit www.microportortho.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version